Following evaluations that began in 4Q18, Alphatec commenced commercial release of InVictus™, a spinal fixation platform that can address a range of pathologies via minimally invasive (MIS), open or hybrid approaches. This is the seventh of 12 products to be launched within the year.
InVictus is designed to support treatments that meet the clinical needs of each patient across a range of degenerative and complex deformity thoracolumbar pathologies, and it integrates with SafeOp neurophysiology tools to provide objective, actionable, real-time information throughout the procedure for more reproducible spine surgery.
Following evaluations that began in 4Q18, Alphatec commenced commercial release of InVictus™, a spinal fixation platform that can address a range of pathologies via minimally invasive (MIS), open or hybrid approaches. This is the seventh of 12 products to be launched within the year.
InVictus is designed to support treatments that meet the...
Following evaluations that began in 4Q18, Alphatec commenced commercial release of InVictus™, a spinal fixation platform that can address a range of pathologies via minimally invasive (MIS), open or hybrid approaches. This is the seventh of 12 products to be launched within the year.
InVictus is designed to support treatments that meet the clinical needs of each patient across a range of degenerative and complex deformity thoracolumbar pathologies, and it integrates with SafeOp neurophysiology tools to provide objective, actionable, real-time information throughout the procedure for more reproducible spine surgery.
Copy to clipboard 
